These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7690683)

  • 1. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics.
    Crews JC; Sweeney NJ; Denson DD
    Cancer; 1993 Oct; 72(7):2266-72. PubMed ID: 7690683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
    Zimmermann C; Seccareccia D; Booth CM; Cottrell W
    J Pain Palliat Care Pharmacother; 2005; 19(2):25-31. PubMed ID: 16061458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone.
    Thomas Z; Bruera E
    J Pain Symptom Manage; 1995 May; 10(4):315-7. PubMed ID: 7541438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the clinical use of methadone for cancer pain.
    Ripamonti C; Zecca E; Bruera E
    Pain; 1997 Apr; 70(2-3):109-15. PubMed ID: 9150283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical opioids differentially induce co-internalization of μ- and δ-opioid receptors.
    Bao F; Li CL; Chen XQ; Lu YJ; Bao L; Zhang X
    Mol Pain; 2018; 14():1744806918769492. PubMed ID: 29587571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance.
    Dutta R; Lunzer MM; Auger JL; Akgün E; Portoghese PS; Binstadt BA
    Arthritis Res Ther; 2018 Jul; 20(1):154. PubMed ID: 30053832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study.
    Rhondali W; Tremellat F; Ledoux M; Ciais JF; Bruera E; Filbet M
    J Palliat Med; 2013 Nov; 16(11):1382-7. PubMed ID: 24116946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of opioid tolerance -- molecular mechanisms and clinical consequences].
    Freye E; Latasch L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Jan; 38(1):14-26. PubMed ID: 12522725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients.
    Viet CT; Dang D; Aouizerat BE; Miaskowski C; Ye Y; Viet DT; Ono K; Schmidt BL
    J Pain; 2017 Sep; 18(9):1046-1059. PubMed ID: 28456745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antinociceptive profiles of mu and kappa opioid agonists in a rat tooth pulp stimulation procedure.
    Steinfels GF; Cook L
    J Pharmacol Exp Ther; 1986 Jan; 236(1):111-7. PubMed ID: 2867210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The plasticity of the association between mu-opioid receptor and glutamate ionotropic receptor N in opioid analgesic tolerance and neuropathic pain.
    Sánchez-Blázquez P; Rodríguez-Muñoz M; Berrocoso E; Garzón J
    Eur J Pharmacol; 2013 Sep; 716(1-3):94-105. PubMed ID: 23499699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid Rotation to Methadone for Refractory Cancer Pain: A Case Series.
    Khoo SY; Aziz FA; Nambbiar P
    J Pain Palliat Care Pharmacother; 2019; 33(3-4):125-130. PubMed ID: 31638444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using methadone to treat opioid-induced hyperalgesia and refractory pain.
    Axelrod DJ; Reville B
    J Opioid Manag; 2007; 3(2):113-4. PubMed ID: 17520991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone: Maximizing Safety and Efficacy for Pain Control in Patients with Cancer.
    McPherson ML; Costantino RC; McPherson AL
    Hematol Oncol Clin North Am; 2018 Jun; 32(3):405-415. PubMed ID: 29729777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.
    Mercadante S; Casuccio A; Agnello A; Serretta R; Calderone L; Barresi L
    J Clin Oncol; 1998 Nov; 16(11):3656-61. PubMed ID: 9817288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative dilemma: challenges of the management of a patient on mega doses of morphine and methadone.
    Kaye AD; Alian AA; Vadivelu N; Chung KS
    J Opioid Manag; 2014; 10(1):69-72. PubMed ID: 24604572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
    Adams JU; Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes.
    Bolan EA; Tallarida RJ; Pasternak GW
    J Pharmacol Exp Ther; 2002 Nov; 303(2):557-62. PubMed ID: 12388636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.